{"id":654607,"date":"2023-06-07T13:14:01","date_gmt":"2023-06-07T13:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=654607"},"modified":"2023-06-07T13:14:01","modified_gmt":"2023-06-07T13:14:01","slug":"oncolytic-virus-competitive-landscape-clinical-trials-growth-and-key-companies-companies-genelux-corporation-candel-therapeutics-cg-oncolgy-dnatrix-sillajen-biotherapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/oncolytic-virus-competitive-landscape-clinical-trials-growth-and-key-companies-companies-genelux-corporation-candel-therapeutics-cg-oncolgy-dnatrix-sillajen-biotherapeutics_654607.html","title":{"rendered":"Oncolytic Virus Competitive Landscape Clinical Trials, Growth, and Key Companies | Companies- Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Oncolytic Virus Competitive Landscape Clinical Trials, Growth, and Key Companies | Companies- Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Oncolytic Virus Competitive Landscape Clinical Trials, Growth, and Key Companies | Companies- Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cOncolytic Virus &#8211; Competitive landscape, 2022\u201d report provides comprehensive insights about 150+ companies and 175+ drugs in Oncolytic Virus Competitive landscape<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/oncolytic-virus-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Takeaways from the Complicated Skin And Soft Tissue Infections Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Over 150+ Companies and 175 + Pipeline Drugs for Complicated Skin And Soft Tissue Infections are in various stages of development, and their anticipated acceptance in the Complicated Skin And Soft Tissue Infections market would significantly increase market revenue.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Leading Complicated Skin And Soft Tissue Infections companies developing novel drug candidates to improve the Complicated Skin And Soft Tissue Infections treatment landscape includes Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Virogin Biotech and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Promising Complicated Skin And Soft Tissue Infections pipeline therapies in various stages of development include Pexa-Vec and many others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/oncolytic-virus-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Oncolytic Virus&nbsp; Infections Overview<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Oncolytic viruses (OVs) are organisms able to identify, infect, and lyse different cells in the tumor environment, aiming to stabilize and decrease the tumor progression. They are able to infect abnormal cells through specific targets, such as nuclear transcription factors and among them human telomerase reverse transcriptase, prostate specific antigen, cyclooxygenase-2, osteocalcin, and surface markers as prostate-specific membrane antigen, folate receptor, CD20, endothelial growth factor receptor, and Her2\/neu, which are substances produced by the tumor cells. Furthermore, the deletion of pathogenic viral genes in the laboratory in order to increase the selectivity to the tumor cells and decrease the aggressiveness of the OVs to normal tissues is also possible.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/7f7c109e0f3d07c2db5a4ff78cd845bb.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/oncolytic-virus-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Complicated Skin And Soft Tissue Infections Pipeline Therapies and Key Companies<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">SillaJen, Inc. : Pexa-Vec<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Candel Therapeutics: CAN-2409<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CG Oncology: Virogin Biotech<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1 Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2 Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3 Oncolytic Virus : Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3.1Introduction of Oncolytic virus<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3.2Different types of Oncolytic virus<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3.3Mode of action of Oncolytic viruses<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3.4Application of Oncolytic viruses<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4 Oncolytic Virus Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4.1Comparative Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5 Oncolytic Virus Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5.1Assessment by Product Type<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5.2Assessment by Stage and Product Type<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5.3Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5.4Assessment by Stage and Route of Administration<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5.5Assessment by Molecule Type<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5.6Assessment by Stage and Molecule Type<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6 Oncolytic Virus &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7 SillaJen, Inc.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7.1Company overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7.2Product in development<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8 Pexa-Vec : SillaJen, Inc.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8.1Product Description<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8.2Research and Development<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8.3Product Development Activities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9Candel Therapeutics<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9.1Company overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9.2Product in development<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10 CAN-2409: Candel Therapeutics<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10.1Product Description<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10.2Research and Development<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11 CG Oncology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11.1Company overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11.2Product in development<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12 CG0070: CG Oncology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12.1Product Description<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12.2Research and Development<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12.3Product Development Activities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13 Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13.1Comparative Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Oncolytic Virus Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Oncolytic Virus Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Oncolytic Virus Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Oncolytic Virus Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Oncolytic Virus Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Oncolytic Virus Analyst Views<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Oncolytic Virus Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Appendix<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=oncolytic-virus-competitive-landscape-clinical-trials-growth-and-key-companies-companies-genelux-corporation-candel-therapeutics-cg-oncolgy-dnatrix-sillajen-biotherapeutics\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=oncolytic-virus-competitive-landscape-clinical-trials-growth-and-key-companies-companies-genelux-corporation-candel-therapeutics-cg-oncolgy-dnatrix-sillajen-biotherapeutics\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u201cOncolytic Virus &#8211; Competitive landscape, 2022\u201d report provides comprehensive insights about 150+ companies and 175+ drugs in Oncolytic Virus Competitive landscape Key Takeaways from the Complicated Skin And Soft Tissue Infections Pipeline Report Over 150+ &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/oncolytic-virus-competitive-landscape-clinical-trials-growth-and-key-companies-companies-genelux-corporation-candel-therapeutics-cg-oncolgy-dnatrix-sillajen-biotherapeutics_654607.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,403,404],"tags":[],"class_list":["post-654607","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/654607","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=654607"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/654607\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=654607"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=654607"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=654607"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}